vect-horus.com Report : Visit Site

Technical data of the vect-horus.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host vect-horus.com. Currently, hosted in Bulgaria and its service provider is Etropol Cabel Company Ltd. .

the related websites

csmres.co.uk morganshotel.co.uk dailymail.co.uk globalchange.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

navigation about us mission and scientific approach applications team founders & management scientific advisory board technology vect-horus' platforms ip & publications r&d; programs pipeline partnering founding & academic partners industrial & financial partners news contact contact form an innovative delivery technology rmt-based vectors… … to deliver drugs and imaging agents into organs cns diseases and cancers breaking barriers previous next about vect-horus breaking barriers vect-horus is a biotechnology company that designs and develops peptide-based vectors that facilitate the delivery of drugs or imaging agents into organs, notably into the brain, and to tumors. the vectors target receptors involved in “receptor mediated transport” (rmt, a physiological system for the transport into cells of endogenous substances). by combining drugs or imaging agents to its vectors, vect-horus allows them to cross biological barriers that restrict access to their target, notably the blood-brain barrier (bbb). the company has already established the proof of concept of its technology in animal models by vectorizing an endogenous neuropeptide, which led to a novel proprietary drug-candidate with neuroprotective properties. this first drug-candidate has now entered regulatory preclinical phase. founded in 2005, by alexandre tokay, ceo, and dr. michel khrestchatisky, scientific advisor, vect-horus is a spin-off of the neurobiology laboratory directed by dr. michel khrestchatisky (umr7529, cnrs and aix-marseille university). based in marseille, france, the company has 30 employees, mostly in r&d, and develops academic collaborations with the cnrs, inserm and cea as well as industrial partnerships. vect-horus was recently identified by the cnrs as one of the 15 success stories among 1,000 spin-offs from its laboratories ( see press release ). mission and ambition vect-horus’ mission is to provide innovative delivery technologies that overcome biological barriers, primarily the bbb, opening new avenues in the treatment and imaging of central nervous system diseases and cancers. vect-horus’ ambition is to become a leader in the promising market of therapeutics and diagnostics delivery, especially in the brain. scientific approach the blood-brain barrier (bbb) prevents entry into the brain of most toxic molecules and infectious agents but also restricts very effectively the passage of imaging or therapeutic agents from blood to brain. an estimated 98% of all active drugs and virtually all biomolecules developed by the biopharmaceutical industry, including peptides, proteins and therapeutic antibodies, are not able to cross the bbb. the scientific approach of vect-horus is based on the principle that complex biological barriers, the first of which the bbb, are not only physical barriers, but also functional barriers whose natural transport mechanisms may be advantageously used to deliver drugs or imaging agents into their target territory: organ, brain, tumor, etc. to overcome biological barriers and thus reduce the attrition rate of cns drugs, vect-horus combines molecules of interest to peptide-vectors that specifically target receptors involved in receptor mediated transport (rmt). this approach is presently considered as one of the most effective and safest way to by-pass the bbb and deliver biomolecules to the brain. applications depending on the targeted receptors and vectors, vect-horus’ technology has the potential to address different organs (brain and others) and pathological conditions including acute or chronic neurodegeneration, rare diseases, cancers… potential to conjugate vectors (vh) to different radionuclides for imaging: spect vh-( 99 mtc, 123 i/ 125 i, 111 in) pet vh-( 68 ga, 18 f, 11 c, 13 n, 15 o) potential to conjugate vectors to different classes of imaging or therapeutic agents: small organic molecules such as fluorophores, anticancer drugs (paclitaxel, doxorubicin...) peptides: neuropeptides, analgesic peptides… proteins: therapeutic proteins, enzyme replacement therapy for rare and orphan diseases, monoclonal antibodies… oligonucleotides: antisense oligos, sirnas, aptamers, morpholinos, ribozymes… team founded in 2005, by alexandre tokay and dr. michel khrestchatisky, the company has 30 employees, mostly in r&d. founders & management alexandre tokay ceo and cofounder dr michel khrestchatisky co-founder and scientific counsel dr. jamal temsamani drug development and corporate scientific advisory board five renowned scientists and experts in neuropharmacology, oncology and molecular engineering bring their expertise to vect-horus pr. jean-michel scherrmann dr. vincent dive pr. jean-pierre benoit dr. mikhail kalinichev pr. pascal hammel technology in close collaboration with top academic research centers (cnrs, cea, inserm), vect-horus has set up a unique screening platform of peptide and nanobody libraries to identify and optimize rmt-based vectors and conjugate them with any type of molecules of interest: small organic molecules, peptides, therapeutic proteins, monoclonal antibodies and oligonucleotides. vect-horus technology advantages: short (down to 8 amino-acids), cyclic, chemically optimized peptides (synthesis of economically viable commercial quantities) high affinity and stable rmt-based vectors (half-life in fresh blood from 1h30 to more than 9h, depending on the vectors) customized conjugates with or without linkers validation in in vitro bbb models and animal models novel, fully patentable, new chemical entities (nces) vect-horus' platforms genetic engineering, molecular & cellular biology, biochemistry development of cell lines expressing specific receptors coupling of large molecules using genetic engineering affinity and stability of drug candidates chemistry of vectors & conjugates chemical coupling with various drugs (small drugs, peptides, proteins, abs) purification & analysis development of cleavable and non-cleavable linkers in vitro bbb models & in vivo bbb technology screening of drugs across the bbb intracellular distribution (parenchyma, microvessels, etc.) confocal imaging pharmacology & in vivo studies brain uptake using in situ brain perfusion model pharmacokinetics and biodistribution in various organs efficacy in animal models (neuroprotection, alzheimer, etc.) intellectual property 3 international patent applications for vectors (2008, 2010, 2013), 2 delivered in europe and usa (2014), fto confirmed 1 international patent application for a vectorised neuroprotective agent (2014) 4 families of patents: peptide derivatives and use thereof as carriers for molecules in the form of conjugates (application wo 2010/046588). issued in the us, europe and south africa. pending in other countries. peptide derivatives, preparation thereof and uses thereof (application wo 2011/131896). issued in france, usa and eurasia. pending in other countries. compositions and methods for drug delivery (application wo 2014/060601). activated neurotensin molecules and the uses thereof (application wo 2015/107182). reviews and scientific publications david m, lécorché p, masse m, faucon a, abouzid k, gaudin n, varini k, gassiot f, ferracci g, jacquot g, vlieghe p, khrestchatisky m. identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos , (feb 27, 2018). molino y, david m, varini k, jabès f, gaudin n, fortoul a, bakloul k, masse m, bernard a, drobecq l, lécorché p, temsamani j, jacquot g, and khrestchatisky m. use of ldl receptor–targeting peptide vectors for in vitro and in vivo cargo transport across the blood-brain barrier. the faseb journal 2017, jan 20, doi: 10.1096/fj.201600827r. jacquot g, lécorché p, malcor jd, laurencin m, smirnova m, varini k, malicet c, gassiot f, faucon a, david m, gaudin n, masse m, ferracci g, dive v, c

URL analysis for vect-horus.com

https://www.vect-horus.com///?tx_typoscriptrendering[context]=%7b%22renderer%22%3a%20%22content%22%7d&data-uid=603&tx_news_pi1[news]=33&chash=b89f7ee2e0403d7ac9c808784af476d1
https://www.vect-horus.com///?tx_typoscriptrendering[context]=%7b%22renderer%22%3a%20%22content%22%7d&data-uid=603&tx_news_pi1[news]=79&chash=d2d9e3b8aa1864f55f74f548a37f25e3
https://www.vect-horus.com///?tx_typoscriptrendering[context]=%7b%22renderer%22%3a%20%22content%22%7d&data-uid=603&tx_news_pi1[news]=19&chash=64baa7614d9bf716d1970fd626a826a4
https://www.vect-horus.com///?tx_typoscriptrendering[context]=%7b%22renderer%22%3a%20%22content%22%7d&data-uid=603&tx_news_pi1[news]=28&chash=a846a240d39292bddf8be3137cc3aa13
https://www.vect-horus.com///?tx_typoscriptrendering[context]=%7b%22renderer%22%3a%20%22content%22%7d&data-uid=603&tx_news_pi1[news]=17&chash=7f91d5ef47da4790b1b06475129ab7ba
https://www.vect-horus.com//#c395
https://www.vect-horus.com///?tx_typoscriptrendering[context]=%7b%22renderer%22%3a%20%22content%22%7d&data-uid=603&tx_news_pi1[news]=66&chash=1ad8eb7426b213a6ca6867a63ed7f69b
https://www.vect-horus.com///?tx_typoscriptrendering[context]=%7b%22renderer%22%3a%20%22content%22%7d&data-uid=603&tx_news_pi1[news]=85&chash=6037b27e2ef095046a6d9c62cde849e3
https://www.vect-horus.com///?tx_typoscriptrendering[context]=%7b%22renderer%22%3a%20%22content%22%7d&data-uid=603&tx_news_pi1[news]=65&chash=d552ed969d8acdbaf8e9ee1bc542b85f
https://www.vect-horus.com//#c573
https://www.vect-horus.com//#c574
https://www.vect-horus.com///?tx_typoscriptrendering[context]=%7b%22renderer%22%3a%20%22content%22%7d&data-uid=603&tx_news_pi1[news]=2&chash=cd5bb94126104a344f7ad194faa95f21
https://www.vect-horus.com//mailto:?subject=this%20site%20has%20my%20full%20attention&body=%0d%0a%0d%0a%0d%0a/u/
https://www.vect-horus.com///?tx_typoscriptrendering[context]=%7b%22renderer%22%3a%20%22content%22%7d&data-uid=603&tx_news_pi1[news]=4&chash=73772bc7a5d30bebe7d6f731c6a46cb7
https://www.vect-horus.com//#page-top

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: vect-horus.com
Registry Domain ID: 124813813_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.ovh.com
Registrar URL: http://www.ovh.com
Updated Date: 2017-06-15T00:16:50.0Z
Creation Date: 2004-07-14T17:42:26.0Z
Registrar Registration Expiration Date: 2018-07-14T17:42:26.0Z
Registrar: OVH, SAS
Registrar IANA ID: 433
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +33.972101007
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Registry Registrant ID:
Registrant Name: VECT-HORUS S.A.S
Registrant Organization: VECT-HORUS S.A.S
Registrant Street: 51 boulevard pierre dramard
Registrant City: MARSEILLE CEDEX 15
Registrant State/Province:
Registrant Postal Code: 13344
Registrant Country: FR
Registrant Phone: +33.684779472
Registrant Phone Ext:
Registrant Fax:
Registrant Fax Ext:
Registrant Email: [email protected]
Registry Admin ID:
Admin Name: VECT-HORUS SAS
Admin Organization: VECT-HORUS SAS
Admin Street: Faculté de Médecine,Secteur Nord
CS80011
51,Bd Pierre Dramard
Admin City: Marseille Cedex 15
Admin State/Province:
Admin Postal Code: 13344
Admin Country: FR
Admin Phone: +33.491698781
Admin Phone Ext:
Admin Fax:
Admin Fax Ext:
Admin Email: [email protected]
Registry Tech ID:
Tech Name: VECT-HORUS SAS
Tech Organization: VECT-HORUS SAS
Tech Street: Faculté de Médecine,Secteur Nord
CS80011
51,Bd Pierre Dramard
Tech City: Marseille Cedex 15
Tech State/Province:
Tech Postal Code: 13344
Tech Country: FR
Tech Phone: +33.491698781
Tech Phone Ext:
Tech Fax:
Tech Fax Ext:
Tech Email: [email protected]
Name Server: ns10.ovh.net
Name Server: dns10.ovh.net
DNSSEC: unsigned
URL of the ICANN WHOIS Data Problem Reporting System:
http://wdprs.internic.net/
>>> Last update of WHOIS database: 2017-06-15T02:16:54.0Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

###############################################################################
#
# Welcome to the OVH WHOIS Server.
#
# whois server : whois.ovh.com check server : check.ovh.com
#
# The data in this Whois is at your disposal with the aim of supplying you the
# information only, that is helping you in the obtaining of the information
# about or related to a domain name registration record. OVH Sas make this
# information available "as is", and do not guarantee its accuracy. By using
# Whois, you agree that you will use these data only for legal purposes and
# that, under no circumstances will you use this data to: (1) Allow, enable,
# or otherwise support the transmission of mass unsolicited, commercial
# advertisement or roughly or requests via the individual mail (courier),
# the E-mail (SPAM), by telephone or by fax. (2) Enable high volume, automated,
# electronic processes that apply to OVH Sas (or its computer systems).
# The copy, the compilation, the re-packaging, the dissemination or the
# other use of the Whois base is expressly forbidden without the prior
# written consent of OVH. Domain ownership disputes should be settled using
# ICANN's Uniform Dispute Resolution Policy: http://www.icann.org/udrp/udrp.htm
# We reserve the right to modify these terms at any time. By submitting
# this query, you agree to abide by these terms. OVH Sas reserves the right
# to terminate your access to the OVH Sas Whois database in its sole
# discretion, including without limitation, for excessive querying of
# the Whois database or for failure to otherwise abide by this policy.
#
# L'outil du Whois est à votre disposition dans le but de vous fournir
# l'information seulement, c'est-à-dire vous aider dans l'obtention de
# l'information sur ou lié à un rapport d'enregistrement de nom de domaine.
# OVH Sas rend cette information disponible "comme est," et ne garanti pas
# son exactitude. En utilisant notre outil Whois, vous reconnaissez que vous
# emploierez ces données seulement pour des buts légaux et ne pas utiliser cet
# outil dans les buts suivant: (1) la transmission de publicité non sollicitée,
# commerciale massive ou en gros ou des sollicitations via courrier individuel,
# le courrier électronique (c'est-à-dire SPAM), par téléphone ou par fax. (2)
# l'utilisation d'un grand volume, automatisé des processus électroniques qui
# soulignent ou chargent ce système de base de données Whois vous fournissant
# cette information. La copie de tout ou partie, la compilation, le
# re-emballage, la dissémination ou d'autre utilisation de la base Whois sont
# expressément interdits sans consentement écrit antérieur de OVH. Un désaccord
# sur la possession d'un nom de domaine peut être résolu en suivant la Uniform
# Dispute Resolution Policy de l'ICANN: http://www.icann.org/udrp/udrp.htm
# Nous nous réservons le droit de modifier ces termes à tout moment. En
# soumettant une requête au Whois vous consentez à vous soumettre à ces termes.

# local time : Saturday, 15-Jul-17 15:00:45 CEST
# gmt time : Saturday, 15-Jul-17 13:00:45 GMT
# last modify : Thursday, 15-Jun-17 04:15:58 CEST
# request from : 192.168.248.249:15883



  REGISTRAR OVH

  REFERRER http://www.ovh.com

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =vect-horus.com

  PORT 43

  SERVER whois.ovh.com

  ARGS vect-horus.com

  PORT 43

  TYPE domain

DOMAIN

  NAME vect-horus.com

NSERVER

  DNS10.OVH.NET 213.251.188.129

  NS10.OVH.NET 213.251.128.129

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

  CHANGED 2017-06-15

  CREATED 2004-07-14

  EXPIRES 2018-07-14

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .